Blood Samples NGS for Baseline Molecular Signature of Anotinib Treated Advanced NSCLC Patients in ALTER0303 Trial | |
Han, B.; Zhao, Y.; Li, K.; Wang, J.; Wang, Q.; Zhang, L.; Shi, J.; Wang, Z.; He, J.; Shi, Y. | |
2017 | |
卷号 | 12期号:11页码:S2279-S2279 |
关键词 | Anlotinib NGS ctDNA |
ISSN号 | 1556-0864 |
DOI | 10.1016/j.jtho.2017.09.1643 |
URL标识 | 查看原文 |
收录类别 | SCIE |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6369540 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Han, B.,Zhao, Y.,Li, K.,et al. Blood Samples NGS for Baseline Molecular Signature of Anotinib Treated Advanced NSCLC Patients in ALTER0303 Trial[J],2017,12(11):S2279-S2279. |
APA | Han, B..,Zhao, Y..,Li, K..,Wang, J..,Wang, Q..,...&Nan, K..(2017).Blood Samples NGS for Baseline Molecular Signature of Anotinib Treated Advanced NSCLC Patients in ALTER0303 Trial.,12(11),S2279-S2279. |
MLA | Han, B.,et al."Blood Samples NGS for Baseline Molecular Signature of Anotinib Treated Advanced NSCLC Patients in ALTER0303 Trial".12.11(2017):S2279-S2279. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论